# KNSA catalysts: Kiniksa Pharmaceuticals International, plc PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/knsa/catalysts

> Kiniksa Pharmaceuticals International, plc (KNSA) has 4 upcoming catalysts. The next is the KPL-387 topline data readout, Dec 2027 to Mar 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Kiniksa Pharmaceuticals International, plc |
| Ticker | KNSA (Nasdaq) |
| SEC CIK | 1730430 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/knsa |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| December 18, 2020 | [ARCALYST (rilonacept) label expansion decision](https://sec-api.dev/pdufa/rilonacept) | KNSA |  | completed, approved | "BLA125249 SUPPL-47 (Efficacy): submission_status AP, submission_status_date 20201218, review_priority PRIORITY; sponsor_name KINIKSA PHARMACEUTICALS (UK), LTD.; product ARCALYST (RILONACEPT)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125249%22)) |
| March 18, 2021 | [ARCALYST (rilonacept) label expansion decision](https://sec-api.dev/pdufa/rilonacept) | KNSA |  | completed, approved | "BLA125249 SUPPL-49 (Efficacy): submission_status AP, submission_status_date 20210318, review_priority PRIORITY; sponsor_name KINIKSA PHARMACEUTICALS (UK), LTD.; product ARCALYST (RILONACEPT)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125249%22)) |
| Jun 2024 | [KPL-387 trial start](https://sec-api.dev/pdufa/kpl-387) | KNSA |  | completed | "In June 2024, we initiated a Phase 1 clinical trial of KPL-387 in healthy volunteers." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1730430/000110465926019168/knsa-20251231x10k.htm)) |
| Jul 2024 | [Abiprubart trial start](https://sec-api.dev/pdufa/abiprubart) | KNSA |  | completed | "In July 2024, we commenced a Phase 2b clinical trial of abiprubart in Sjögren's Disease." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1730430/000155837025001505/knsa-20241231x10k.htm)) |
| February 21, 2025 | [Kiniksa Pharmaceuticals International, plc earnings report](https://sec-api.dev/companies/knsa/catalysts) | KNSA |  | completed | "Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1730430/000110465925016725/tm257489d1_ex99-1.htm)) |
| mid-2025 | [KPL-387 trial start](https://sec-api.dev/pdufa/kpl-387) | KNSA |  | scheduled | "All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding: our plan to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025, with Phase 2 data expected in the second half of 2026, and that we remain on track to meeting such plan; our target profile of monthly dosing via a single subcutaneous injection in a liquid formulation for KPL-387; our belief that" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1730430/000110465925056665/tm2517185d1_ex99-1.htm)) |
| April 29, 2025 | [Kiniksa Pharmaceuticals International, plc earnings report](https://sec-api.dev/companies/knsa/catalysts) | KNSA |  | completed | "Reports First Quarter 2025 Financial Results and Recent Portfolio Execution" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1730430/000110465925040641/tm2513395d1_ex99-1.htm)) |
| Jul 2025 | [KPL-387 trial start](https://sec-api.dev/pdufa/kpl-387) | KNSA |  | completed | "In July 2025, we initiated our Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis, beginning with the Phase 2 dose-focusing portion of the study." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1730430/000110465926019168/knsa-20251231x10k.htm)) |
| July 29, 2025 | [Kiniksa Pharmaceuticals International, plc earnings report](https://sec-api.dev/companies/knsa/catalysts) | KNSA |  | completed | "Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1730430/000110465925071413/tm2521890d1_ex99-1.htm)) |
| October 28, 2025 | [Kiniksa Pharmaceuticals International, plc earnings report](https://sec-api.dev/companies/knsa/catalysts) | KNSA |  | completed | "Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1730430/000110465925102834/tm2529531d1_ex99-1.htm)) |
| February 24, 2026 | [Kiniksa Pharmaceuticals International, plc earnings report](https://sec-api.dev/companies/knsa/catalysts) | KNSA |  | completed | "Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1730430/000173043026000014/knsa-20260224xex99d1.htm)) |
| April 28, 2026 | [Kiniksa Pharmaceuticals International, plc earnings report](https://sec-api.dev/companies/knsa/catalysts) | KNSA |  | completed | "Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1730430/000173043026000017/knsa-20260428xex99d1.htm)) |
| June 19, 2026 | [Kiniksa Pharmaceuticals International, plc PDUFA date](https://sec-api.dev/companies/knsa/catalysts) | KNSA |  | scheduled | "Since then we have worked to qualify Samsung Biologics Co., Ltd. ("Samsung") as our replacement contract development and manufacturing organization ("CDMO") and, in April 2026, the FDA accepted the supplemental biologics license application related to such technology transfer and assigned a Prescription Drug User Fee Act target action date of June 19, 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1730430/000110465926050359/knsa-20260331x10q.htm)) |
| July 28, 2026 | [Kiniksa Pharmaceuticals International, plc earnings report](https://sec-api.dev/companies/knsa/catalysts) | KNSA |  | completed | "Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1730430/000173043026000031/knsa-20260728xex99d1.htm)) |
| late 2026 | [KPL-387 trial start](https://sec-api.dev/pdufa/kpl-387) | KNSA |  | scheduled | "our expectation to have data from the Phase 2 dose-focusing portion of our clinical trial of KPL-387 in recurrent pericarditis in the second half of 2026, and our plan to initiate the pivotal portion of the trial thereafter" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1730430/000110465925071413/tm2521890d1_ex99-1.htm)) |
| late 2026 | [KPL-1161 trial start](https://sec-api.dev/pdufa/kpl-1161) | KNSA |  | scheduled | "Kiniksa expects to initiate a Phase 1 first-in-human clinical trial of KPL-1161 with a target profile of quarterly subcutaneous (SC) dosing by the end of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1730430/000173043026000037/knsa-ex99d1.htm)) |
| October 27, 2026 | [Kiniksa Pharmaceuticals International, plc earnings report](https://sec-api.dev/companies/knsa/catalysts) | KNSA |  | completed | "Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1730430/000173043026000037/knsa-ex99d1.htm)) |
| Dec 2027 to Mar 2028 | [KPL-387 topline data readout](https://sec-api.dev/pdufa/kpl-387) | KNSA | Pericarditis; Pericarditis Acute; Recurrent Pericarditis | scheduled | "NCT07010159 (Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor Kiniksa Pharmaceuticals International, plc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07010159)) |
| Dec 2027 to Mar 2028 | [KPL-387 topline data readout](https://sec-api.dev/pdufa/kpl-387) | KNSA | Recurrent Pericarditis; Heart Diseases; Pericarditis | scheduled | "NCT07288216 (Transition to KPL-387 Monotherapy Dosing & Administration Study): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor Kiniksa Pharmaceuticals International, plc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07288216)) |
| December 2027 | [KPL-387 primary completion](https://sec-api.dev/pdufa/kpl-387) | KNSA | Pericarditis; Pericarditis Acute; Recurrent Pericarditis | scheduled | "NCT07010159 (Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor Kiniksa Pharmaceuticals International, plc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07010159)) |
| December 2027 | [KPL-387 primary completion](https://sec-api.dev/pdufa/kpl-387) | KNSA | Recurrent Pericarditis; Heart Diseases; Pericarditis | scheduled | "NCT07288216 (Transition to KPL-387 Monotherapy Dosing & Administration Study): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor Kiniksa Pharmaceuticals International, plc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07288216)) |

## Drugs

- [Abiprubart](https://sec-api.dev/pdufa/abiprubart): 
- [KPL-1161](https://sec-api.dev/pdufa/kpl-1161): 
- [KPL-387](https://sec-api.dev/pdufa/kpl-387): Pericarditis, Recurrent Pericarditis
- [ARCALYST (rilonacept)](https://sec-api.dev/pdufa/rilonacept): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/knsa/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "KNSA catalysts: Kiniksa Pharmaceuticals International, plc PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/knsa/catalysts

```bibtex
@misc{secapidev_companies_knsa_catalysts_20261116,
  title        = {KNSA catalysts: Kiniksa Pharmaceuticals International, plc PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/knsa/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_knsa_catalysts_20261116","title":"KNSA catalysts: Kiniksa Pharmaceuticals International, plc PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/knsa/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
